Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.

van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT.

Clin Rheumatol. 2012 Dec;31(12):1677-82. doi: 10.1007/s10067-012-2072-7. Epub 2012 Sep 1.

PMID:
22941219
2.

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

Gorman JD, Sack KE, Davis JC Jr.

N Engl J Med. 2002 May 2;346(18):1349-56.

3.

[Clinical study of etanercept for treating ankylosing spondylitis].

Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51. Chinese.

4.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.

Rheumatology (Oxford). 2005 Mar;44(3):342-8. Epub 2004 Nov 23. Erratum in: Rheumatology (Oxford). 2005 Apr;44(4):569.

PMID:
15561737
5.

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.

Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP.

Joint Bone Spine. 2008 Dec;75(6):737-9. doi: 10.1016/j.jbspin.2007.12.009. Epub 2008 Aug 6.

PMID:
18693125
6.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

7.

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.

8.

Multiple sclerosis following etanercept treatment for ankylosing spondylitis.

Pfueller CF, Seipelt E, Zipp F, Paul F.

Scand J Rheumatol. 2008 Sep-Oct;37(5):397-9. doi: 10.1080/03009740802136164. No abstract available.

PMID:
18720264
9.

Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.

Haraoui B, Krelenbaum M.

Semin Arthritis Rheum. 2009 Dec;39(3):176-81. doi: 10.1016/j.semarthrit.2008.06.004. Epub 2008 Aug 15.

PMID:
18706681
10.

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.

Ann Rheum Dis. 2008 Mar;67(3):346-52. Epub 2007 Oct 29.

11.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
12.

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.

Braun J, McHugh N, Singh A, Wajdula JS, Sato R.

Rheumatology (Oxford). 2007 Jun;46(6):999-1004. Epub 2007 Mar 27.

PMID:
17389658
13.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.

Ann Rheum Dis. 2004 Dec;63(12):1594-600. Epub 2004 Sep 2.

14.

Development of sarcoidosis following etanercept treatment: a report of three cases.

Skoie IM, Wildhagen K, Omdal R.

Rheumatol Int. 2012 Apr;32(4):1049-53. doi: 10.1007/s00296-009-1349-x. Epub 2010 Jan 9.

PMID:
20062997
15.

Etanercept: new indication. For ankylosing spondylitis: another option.

[No authors listed]

Prescrire Int. 2005 Jun;14(77):92-3.

PMID:
15981387
16.

Etanercept in adult patients with early onset ankylosing spondylitis.

Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.

J Rheumatol. 2006 Aug;33(8):1634-6.

PMID:
16881118
17.

Anti-TNF-alpha therapy for ankylosing spondylitis.

Son JH, Cha SW.

Clin Orthop Surg. 2010 Mar;2(1):28-33. doi: 10.4055/cios.2010.2.1.28. Epub 2010 Feb 4.

18.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S; Etanercept Study 314 Investigators.

Ann Rheum Dis. 2006 Dec;65(12):1572-7. Epub 2006 Sep 12.

19.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

20.

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.

Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B.

Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.

Supplemental Content

Support Center